Every 10-Q that ClearPoint Neuro, Inc. (CLPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLPT filings page.
ClearPoint Neuro, Inc. reported Q2 2026 total revenue of $10.9 million, up from $9.2 million in Q2 2025, and six‑month revenue of $23.0 million versus $17.7 million a year earlier. Growth was driven by neurosurgery navigation and therapy revenue of $5.6 million, up 62%, and capital equipment and software revenue of $1.3 million.
Biologics and drug delivery revenue was $4.0 million, down from $4.7 million due to a large prior‑year order that did not repeat. Gross profit was $6.7 million with a 62% gross margin. Operating loss widened to $10.2 million, and net loss to $11.3 million, or $(0.38) per share, as research and development, sales and marketing, and general and administrative expenses all increased.
At June 30, 2026, cash and cash equivalents were $29.4 million, total assets $86.7 million, and long‑term notes payable had a carrying amount of $50.2 million with an effective interest rate of 11.3%. The company recorded net cash used in operating activities of $15.0 million for the first half of 2026 and concluded its existing cash and cash equivalents are sufficient to support operations and meet obligations for at least the next twelve months from the date of issuance of these financial statements.
ClearPoint Neuro, Inc. reports first-quarter 2026 results showing strong top-line growth but continued operating losses. Total revenue rose to $12.1 million from $8.5 million a year earlier, a 43% increase, driven by higher neurosurgery navigation, therapy, and capital equipment sales, including contributions from the IRRAflow and Prism platforms.
Biologics and drug delivery revenue was stable at $4.8 million, while neurosurgery navigation and therapy revenue jumped 80% to $5.9 million and capital equipment and software revenue rose 177% to $1.4 million. Gross margin improved to 64% from 60% as lower excess and obsolete inventory charges offset higher volumes.
Operating expenses grew sharply as the company invested in research, sales, and infrastructure following the IRRAS acquisition. Research and development costs increased to $4.5 million, sales and marketing to $6.7 million, and general and administrative to $5.0 million. Net loss widened to $9.6 million from $6.0 million, or $0.32 per share versus $0.22 per share. Cash, cash equivalents, and restricted cash totaled $36.5 million at quarter-end, and management believes current liquidity is sufficient for at least twelve months under its forecasts.
ClearPoint Neuro (CLPT) reported Q3 results and announced a pending acquisition. Revenue was $8.861 million, up from $8.122 million a year ago, driven by higher neurosurgery navigation disposables and increased services. Gross profit was $5.600 million. The company posted a net loss of $5.891 million versus $4.974 million last year as operating expenses rose.
For the nine months, revenue reached $26.561 million (vs. $23.619 million), with product revenue of $16.649 million and service and other revenue of $9.912 million. Cash and cash equivalents were $38.221 million, reflecting an initial 2025 Note Purchase Agreement draw that yielded approximately $28.7 million in net proceeds and a registered direct equity raise of approximately $3.3 million. Long‑term note payable stood at $29.203 million.
Strategic update: On November 6, 2025, CLPT agreed to acquire IRRAS for $5.0 million in cash at closing and 1,325,000 shares, plus earnouts tied to future net sales. On November 5, 2025, CLPT also arranged access to an additional $20.0 million under its existing note agreement, conditioned on the IRRAS closing. Shares outstanding were 28,423,308 as of October 27, 2025.
ClearPoint Neuro reported total revenue of $9.2 million for the quarter, up 17% from $7.9 million a year earlier, led by product revenue of $6.0 million (up 21%). Gross profit was $5.6 million with a 60% margin, slightly below prior-year margins. The company recorded a net loss of $5.8 million for the quarter (basic and diluted loss per share $0.21) and a six-month net loss of $11.9 million (EPS $0.42), driven by higher research and development, sales and marketing, and general and administrative expenses.
Liquidity strengthened to $41.5 million in cash and equivalents at June 30, 2025 after a registered direct equity sale that raised ~$3.3 million net and an initial note issuance that provided approximately $28.7 million net. The company entered a Note Purchase Agreement providing up to $105.0 million of potential notes (initial $30.0 million funded) secured by substantially all assets and carrying PIK interest and future revenue-sharing provisions; management states existing cash is sufficient for at least the next twelve months. Accumulated deficit totaled $203.2 million.